Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma.
Tiffany C LeeKoffi WimaMackenzie C MorrisMichael E JohnstonShimul A ShahSyed A AhmadSameer H PatelGregory C WilsonPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2020)
Since the INT-0116 and MAGIC trials, utilization of evidence-based treatments for resectable gastric adenocarcinoma has increased, with perioperative chemotherapy surpassing adjuvant CRT as the preferred practice. However, overall utilization of these regimens remains quite low nationally despite association with improved OS.